TTTaufik Ramdani Tohari

Taufik Ramdani Tohari

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Taufik Ramdani Tohari has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Antonius Eko Nugroho

    Lab-on-Chip Group, Biomedical Engineering Department, Institute of Technology, Bandung 40132, Indonesia

    1 shared publication
  • Brian Yuliarto

    Advanced Functional Materials Research Group, Faculty of Industrial Technology, Institut Teknologi Bandung, Bandung 40132, Indonesia

    1 shared publication
  • Gilang Gumilar

    Research Center for Electronics, The National Research and Innovation Agency (BRIN), Bandung, Jawa Barat, Indonesia

    1 shared publication
  • Irvan Faizal

    Research Cente for Vaccine and Drugs, National Research and Innovation Agency Republic of Indonesia, Tangerang Selatan 15314, Indonesia

    1 shared publication
  • Isa Anshori

    Affiliations Lab on Chip Laboratory, Biomedical Engineering Department, School of Electrical Engineering and Informatics, Institut Teknologi Bandung, Bandung, Indonesia, Research Center for Nanoscience and Nanotechnology, Institut Teknologi Bandung, Bandung, Indonesia, ITB Center for Health snd Sports Technology (PTKK-ITB), Institut Teknologi Bandung, Bandung, Indonesia

    1 shared publication
  • Muhammad Yusuf

    Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Padjadjaran, Bandung 45363, Indonesia

    1 shared publication

Latest Publications

  • Open Access

    Development of a Single-Chain Variable Fragment of CR3022 for a Plasmonic-Based Biosensor Targeting the SARS-CoV-2 Spike Protein

    by Taufik Ramdani Tohari, Isa Anshori, Umi Baroroh, Antonius Eko Nugroho, Gilang Gumilar, Shinta Kusumawardani, Sari Syahruni, Brian Yuliarto, Wyanda Arnafia, Irvan Faizal, et al.

    Two years after SARS-CoV-2 caused the first case of COVID-19, we are now in the “new normal” period, where people’s activity has bounced back, followed by the easing of travel policy restrictions. The lesson learned is that the wide availability of accurate and rapid testing procedures is crucial to overcome possible outbreaks in the future. Therefore, many laboratories worldwide have been racing to develop a new point-of-care diagnostic test. To aid continuous innovation, we developed a plasmonic-based biosensor designed explicitly for portable Surface Plasmon Resonance (SPR). In this study, we designed a single chain variable fragment (scFv) from the CR3022 antibody with a particular linker that inserted a cysteine residue at the second position. It caused the linker to have a strong affinity to the gold surface through thiol-coupling and possibly become a ready-to-use bioreceptor toward a portable SPR gold chip without purification steps. The theoretical affinity of this scFv on spike protein was −64.7 kcal/mol, computed using the Molecular Mechanics Generalized Born Surface Area (MM/GBSA) method from the 100 ns molecular dynamics trajectory. Furthermore, the scFv was produced in Escherichia coli BL21 (DE3) as a soluble protein. The binding activity toward Spike Receptor Binding Domain (RBD) SARS-CoV-2 was confirmed with a spot-test, and the experimental binding free energy of −10.82 kcal/mol was determined using portable SPR spectroscopy. We hope this study will be useful in designing specific and low-cost bioreceptors, particularly early in an outbreak when the information on antibody capture is still limited.